ArticleCureus2025
Dural-Based Glioblastoma Recurrence: An Illustrative Case and Review of Literature.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma is a common primary central nervous system tumor with an expected median overall survival of 12 to 15 months. Radiographically, high-grade gliomas classically present as heterogeneous ring-enhancing lesions in the brain parenchyma with central necrosis on MRI. In rare cases, other peripheral tumors can also present with a meningeal attachment with evidence of a dural tail. Histologically, the tumor has malignant features such as atypical cells, nuclear hyperchromasia, increased mitotic figures, angiogenesis, and necrotic regions. We present a 49-year-old male with a history of a left frontotemporal glioblastoma isocitrate dehydrogenase (IDH) wild type and O6-methylguanine-DNA methyltransferase (MGMT) unmethylated (~ 95% of gross total). The patient subsequently underwent chemotherapy with temozolomide and external beam radiation therapy with 60 Gy over 30 fractions. The patient presented eight months post-index resection with recurrence and dural invasion. The pathology report demonstrated adherent dural components. The patient was subsequently placed on bevacizumab. There is a paucity of literature regarding dural-based spread of glioblastoma along the dura after an initial resection. Additionally, there is difficulty in differentiating these tumors from meningiomas, with resultant misdiagnosis and management. It is critical to inform readers of its presence and emphasize the importance of its consideration in the differential diagnosis of dural-based tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.